Table 1.

Change from baseline to week 12 in plasma concentrations of key fatty acids

Plasma fatty acida	IPE 4 g/day			Placebo			Change from baseline, IPE 4 g/day vs placebo, %, P
Concentration, μg/g	Baseline (SD)	Week 12 (SD)	Change (SE)	Baseline (SD)	Week 12 (SD)	Change (SE)
EPA (C20:5n-3)	19.57	144.68	135.98	24.29	24.39	10.43	634.50
n = 43, 51	(6.410)	(56.464)	(5.998)	(29.025)	(25.073)	(5.457)	< 0.0001
DHA (C22:6n-3)	51.80	54.02	2.84	58.54	61.59	4.44	− 1.12
n = 48, 52	(15.369)	(13.842)	(1.852)	(34.274)	(32.907)	(1.743)	0.7820
DPA (C22:5n-3)	20.19	50.45	31.79	21.41	23.83	3.91	143.27
n = 49, 52	(5.573)	(14.172)	(1.794)	(7.999)	(9.403)	(1.714)	< 0.0001
Palmitic (C16:0)	974.49	846.22	− 162.1	1038.7	1100.2	56.28	− 22.87
n = 48, 51	(223.707)	(213.932)	(44.906)	(299.038)	(352.507)	(42.832)	<0.0001
Stearic (C18:0)	278.90	254.07	− 30.83	291.88	304.54	13.52	− 16.16
n = 50, 50	(55.757)	(48.217)	(8.149)	(61.887)	(62.494)	(7.995)	<0.0001
Oleic (C18:1n-9)	979.09	784.41	− 220.0	1011.0	1091.5	66.70	− 29.48
n = 47, 51	(261.606)	(208.940)	(49.146)	(296.705)	(403.343)	(46.802)	< 0.0001
Linoleic (C18:2n-6)	1069.4	922.28	− 152.5	1093.0	1221.8	127.42	− 24.75
n = 50, 52	(262.259)	(200.324)	(38.151)	(258.966)	(350.910)	(36.433)	< 0.0001
AA (C20:4n-6)	282.84	223.26	− 60.69	306.96	328.17	26.25	− 30.87
n = 50, 52	(71.080)	(65.530)	(6.295)	(74.556)	(67.119)	(6.124)	< 0.0001
AA/EPA	16.23	1.61	− 14.17	16.97	16.63	0.60	− 90.64
n = 47, 50	(6.665)	(0.795)	(0.556)	(6.785)	(6.638)	(0.532)	< 0.0001

^aPatient numbers (n) are reported for IPE 4 g/day and placebo, respectively

Mean and SD are reported for baseline and end-of-treatment values; least squares means and SEs are reported for changes from baseline; least squares means are reported for percent changes from baseline vs. placebo

AA arachidonic acid, DHA docosahexaenoic acid, DPA docosapentaenoic acid, EPA eicosapentaenoic acid, IPE icosapent ethyl, SD standard deviation, SE standard error